These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24239480)

  • 21. Medicines containing pharmaceutical excipients with known effects: a French review.
    Fusier I; Tollier C; Husson MC
    Pharm World Sci; 2003 Aug; 25(4):152-5. PubMed ID: 12964493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates.
    Mulla H; Yakkundi S; McElnay J; Lutsar I; Metsvaht T; Varendi H; Nellis G; Nunn A; Duncan J; Pandya H; Turner M
    Pharm Res; 2015 Mar; 32(3):1084-93. PubMed ID: 25236342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence and pattern of pharmaceutical and excipient exposure in a neonatal unit in Slovenia.
    Fister P; Urh S; Karner A; Krzan M; Paro-Panjan D
    J Matern Fetal Neonatal Med; 2015; 28(17):2053-61. PubMed ID: 25316561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2020; 30(6):400-408. PubMed ID: 32376520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safe excipient exposure in neonates and small children - protocol for the SEEN project.
    Valeur KS; Hertel SA; Lundstrøm KE; Holst H
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potentially harmful excipients in prescribed medications in a Neonatal Intensive Care Unit in Kosovo and available safer alternatives.
    Koshi B; Grapci AD; Nebija D; Selmani PB; Morina R; Crcarevska MS; Dodov MG; Raichki RS
    Turk J Pediatr; 2022; 64(1):49-58. PubMed ID: 35286030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach.
    Allegaert K; Cosaert K; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5674-9. PubMed ID: 26323412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):86-100. PubMed ID: 32327401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethanol exposure through medicines commonly used in paediatrics.
    Christiansen N
    Arch Dis Child Educ Pract Ed; 2015 Apr; 100(2):101-4. PubMed ID: 25147324
    [No Abstract]   [Full Text] [Related]  

  • 31. A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia.
    Sviestina I; Mozgis D
    Eur J Hosp Pharm; 2018 Jul; 25(4):176-182. PubMed ID: 31157015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Investigation on Exposure to Potentially Harmful Excipients by Injection Drug Administration in Children Under 2 Years of Age and Analysis of Association with Adverse Events: A Single-Center, Retrospective Observational Study.
    Saito J; Nakamura H; Akabane M; Yamatani A
    Ther Innov Regul Sci; 2024 Mar; 58(2):316-335. PubMed ID: 38055156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing.
    Bejarano A; Hewa Nadungodage C; Wang F; Catlin AC; Hoag SW
    AAPS PharmSciTech; 2019 Jun; 20(6):223. PubMed ID: 31214878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excipients and Adverse Events.
    Allen LV
    Int J Pharm Compd; 2023; 27(5):382-385. PubMed ID: 37816181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic excipients: Importance of clinical awareness of inactive ingredients.
    Ionova Y; Wilson L
    PLoS One; 2020; 15(6):e0235076. PubMed ID: 32584876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan.
    Chang LC; Kang JJ; Gau CS
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):947-52. PubMed ID: 26387930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates.
    Nellis G; Metsvaht T; Varendi H; Lass J; Duncan J; Nunn AJ; Turner MA; Lutsar I
    Paediatr Drugs; 2016 Jun; 18(3):221-30. PubMed ID: 27099961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxic excipients in medications for neonates in Brazil.
    Souza A; Santos D; Fonseca S; Medeiros M; Batista L; Turner M; Coelho H
    Eur J Pediatr; 2014 Jul; 173(7):935-45. PubMed ID: 24500397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential aspects of chitosan as pharmaceutical excipient.
    Ray SD
    Acta Pol Pharm; 2011; 68(5):619-22. PubMed ID: 21928704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical excipient development: the need for preclinical guidance.
    Baldrick P
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.